NUDCD3

Across TCGA pan-cancer cohorts, NUDCD3 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated NUDCD3 data layer compared with 21 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher NUDCD3 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated NUDCD3 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

CCRCC, UCEC, and PDAC are the cancer types where NUDCD3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	II,III,IV	0.443	0.878	<.001	31	view →
UCEC	OS	Tertile	All	0.831	0.973	.020	4	view →
PDAC	DFS	Tertile	III,IV	1.000	0.550	.026	3	view →
LUAD	OS	Median	III,IV	0.265	1.000	.034	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

NUDCD3–CCRCC (OS)

Open the CCRCC breakdown →